表紙:表皮水疱症:パイプライン製品の分析
市場調査レポート
商品コード
213080

表皮水疱症:パイプライン製品の分析

Epidermolysis Bullosa (Dermatology) - Drugs In Development, 2021

出版日: | 発行: Global Markets Direct | ページ情報: 英文 169 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
表皮水疱症:パイプライン製品の分析
出版日: 2021年07月30日
発行: Global Markets Direct
ページ情報: 英文 169 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

表皮水疱症(EB)とは線訂正の水疱性障害の一種で、無意識の(ちょっとした)外傷に反応して水疱が形成されるという特徴があります。主な症状として、皮膚上の水疱の形成や、指や爪の奇形・損失、体内(喉・食道・上部気道・胃・腸・尿路など)の水疱形成、掌や踵の皮膚の厚増化(角質増殖症)、頭皮の水疱出現・瘢痕化・毛髪脱落などが挙げられます。主な治療法には抗生物質や外科手術などがあります。

当レポートでは、世界各国での表皮水疱症治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

イントロダクション

  • 調査範囲

表皮水疱症の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

表皮水疱症:企業で開発中の治療薬

表皮水疱症:大学/機関で研究中の治療薬

表皮水疱症:パイプライン製品の概況

  • 後期段階の製品
  • 臨床段階の製品
  • 初期段階の製品

表皮水疱症:企業で開発中の製品

表皮水疱症:大学/機関で研究中の製品

表皮水疱症の治療薬開発に従事している企業

  • Birken AG
  • Fibrocell Science, Inc.
  • GlaxoSmithKline Plc
  • InMed Pharmaceuticals Inc.
  • Karus Therapeutics Limited
  • ProQR Therapeutics N.V.
  • RegeneRx Biopharmaceuticals, Inc.
  • Scioderm, Inc.
  • Stratatech Corporation
  • TWi Pharmaceuticals, Inc.
  • WAVE Life Sciences Ltd.

表皮水疱症:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

表皮水疱症:最近のパイプライン動向

表皮水疱症:休止中のプロジェクト

表皮水疱症:開発が中止された製品

表皮水疱症:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

List of Tables

List of Tables

  • Number of Products under Development for Epidermolysis Bullosa, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Epidermolysis Bullosa - Pipeline by Abeona Therapeutics Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Aegle Therapeutics Corp, 2021
  • Epidermolysis Bullosa - Pipeline by Almirall SA, 2021
  • Epidermolysis Bullosa - Pipeline by Amniotics AB, 2021
  • Epidermolysis Bullosa - Pipeline by Amryt Pharma Plc, 2021
  • Epidermolysis Bullosa - Pipeline by Anterogen Co Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by Berg LLC, 2021
  • Epidermolysis Bullosa - Pipeline by BioVec Pharma Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Castle Creek Biosciences Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Celularity Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Constant Therapeutics LLC, 2021
  • Epidermolysis Bullosa - Pipeline by CSA Biotechnologies LLC, 2021
  • Epidermolysis Bullosa - Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by Eloxx Pharmaceuticals Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Energenesis Biomedical Co Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by FIBRX Derm Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Holostem Terapie Avanzate SRL, 2021
  • Epidermolysis Bullosa - Pipeline by Immusoft Corp, 2021
  • Epidermolysis Bullosa - Pipeline by InMed Pharmaceuticals Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Kang Stem Biotech Co Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by Krystal Biotech Inc, 2021
  • Epidermolysis Bullosa - Pipeline by LambdaGen Therapeutics, 2021
  • Epidermolysis Bullosa - Pipeline by Mariposa Therapeutics Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by OTR3 SAS, 2021
  • Epidermolysis Bullosa - Pipeline by Palvella Therapeutics LLC, 2021
  • Epidermolysis Bullosa - Pipeline by Panag Pharma Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Phoenix Tissue Repair Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Quoin Pharmaceuticals Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by RegeneRx Biopharmaceuticals Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Relief Therapeutics Holding AG, 2021
  • Epidermolysis Bullosa - Pipeline by RHEACELL GmbH & Co KG, 2021
  • Epidermolysis Bullosa - Pipeline by Shionogi & Co Ltd, 2021
  • Epidermolysis Bullosa - Pipeline by StemRIM Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Therapicon Srl, 2021
  • Epidermolysis Bullosa - Pipeline by TWi Biotechnology Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Vera Therapeutics Inc, 2021
  • Epidermolysis Bullosa - Pipeline by Wings Therapeutics, 2021
  • Epidermolysis Bullosa - Dormant Projects, 2021
  • Epidermolysis Bullosa - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Epidermolysis Bullosa, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021
目次
Product Code: GMDHC13003IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Epidermolysis Bullosa - Drugs In Development, 2021, provides an overview of the Epidermolysis Bullosa (Dermatology) pipeline landscape.

Epidermolysis bullosa (EB) is a group of inherited bullous disorders characterized by blister formation in response to mechanical trauma. Symptoms include blistering of skin, deformity or loss of fingernails and toenails, internal blistering, including on the throat, esophagus, upper airway, stomach, intestines and urinary tract, skin thickening on palms and soles of the feet (hyperkeratosis) and scalp blistering, scarring and hair loss (scarring alopecia). Treatment includes antibiotics, antibiotic and surgery.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Epidermolysis Bullosa - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Epidermolysis Bullosa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Epidermolysis Bullosa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Epidermolysis Bullosa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 10, 2, 2, 13, 8 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 1 molecules, respectively.

Epidermolysis Bullosa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Epidermolysis Bullosa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Epidermolysis Bullosa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Epidermolysis Bullosa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Epidermolysis Bullosa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Epidermolysis Bullosa (Dermatology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Epidermolysis Bullosa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Epidermolysis Bullosa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Epidermolysis Bullosa - Overview
  • Epidermolysis Bullosa - Therapeutics Development
  • Epidermolysis Bullosa - Therapeutics Assessment
  • Epidermolysis Bullosa - Companies Involved in Therapeutics Development
  • Epidermolysis Bullosa - Drug Profiles
  • Epidermolysis Bullosa - Dormant Projects
  • Epidermolysis Bullosa - Discontinued Products
  • Epidermolysis Bullosa - Product Development Milestones
  • Appendix